PDCD1 and inflammation: The absence of hypertension, a condition linked to chronic endothelial inflammation and T‐cell dysfunction, was correlated with improved PD‐1 inhibitor efficacy, suggesting that baseline vascular health may modulate immunotherapy outcomes [39].